SCHEMBL8762006

SCHEMBL8762006

BrCc1ccc(OCc2ccccc2)cc1CBr

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.58
MAOB P27338 9/20 0.54
LMNA P02545 1/20 0.52
CYP1A2 P05177 1/20 0.52
PTGS1 P23219 1/20 0.52
SLC6A2 P23975 1/20 0.52
CYP2C19 P33261 1/20 0.52
PTGS2 P35354 1/20 0.52
SLC6A3 Q01959 1/20 0.52
HIF1A Q16665 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
MAOA P21397 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
NSD2 O96028 1/20 0.50
ABL1 P00519 1/20 0.50
PPARG P37231 1/20 0.50
RIN1 Q13671 1/20 0.50
NCOR2 Q9Y618 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28330023 0.86 ALOX5 (0.54) ALOX5MAOBLMNACYP1A2PTGS1
SCHEMBL694957 0.85 S1PR1 (0.54) ALOX5MAOBLMNACYP1A2PTGS1
SCHEMBL696437 0.85 ALOX5 (0.53) ALOX5MAOBLMNACYP1A2PTGS1
SCHEMBL3775086 0.85 ALOX5 (0.53) ALOX5MAOBLMNACYP1A2PTGS1
SCHEMBL696249 0.85 S1PR1 (0.54) ALOX5MAOBLMNACYP1A2PTGS1
SCHEMBL3219429 0.82 MAOB (0.55) ALOX5MAOBLMNAL3MBTL1MAPT
SCHEMBL694270 0.81 AR (0.51) ALOX5MAOBLMNACYP1A2PTGS1
SCHEMBL8761070 0.79 ALOX5 (0.58) ALOX5MAOBLMNACYP1A2PTGS1
SCHEMBL80829 0.78 MAOB (0.68) ALOX5MAOBMAOALCK
SCHEMBL29411728 0.78 MAOB (0.68) ALOX5MAOBMAOALCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11590084-B2 Microcapsules for controlled delivery of an active pharmaceutical ingredient BIELSKI ROMAN (US) 2023-02-28 US disclosed
US-20190125687-A1 Microcapsules for Controlled Delivery of an Active Pharmaceutical Ingredient BIELSKI ROMAN (US) 2019-05-02 US disclosed
WO-2017192407-A1 MICROCAPSULES FOR CONTROLLED DELIVERY OF AN ACTIVE PHARMACEUTICAL INGREDIENT BIELSKI ROMAN (US) 2017-11-09 WO disclosed
US-5698580-A TREATING DISEASES CAUSED BY RESPIRATORY SYNCYTIAL VIRUS RATIONAL DRUG DESIGN LABORATORIES (JP) 1997-12-16 US disclosed
EP-0770609-A1 ANTIVIRAL AGENT CONTAINING BENZODITHIIN DERIVATIVE AS ACTIVE INGREDIENT Rational Drug Design Laboratories (JP) 1997-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190125687-A1 Microcapsules for Controlled Delivery of an Active Pharmaceutical Ingredient PUF60, SRM, SMS ALOX5 481/4885MAOB 305/4885LMNA 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.